4.19% -0.0218

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스

Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News

Citius Pharmaceuticals defers FDA milestone payment - Investing.com

Citius Pharmaceuticals defers FDA milestone payment By Investing.com - Investing.com UK

Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Financial Metrics Check: Citius Pharmaceuticals Inc (CTXR)’s Ratios for Trailing Twelve Months - The Dwinnex

Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com

Citius Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Canada

There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News

Insider’s View: Deciphering Citius Pharmaceuticals Inc (CTXR)’s Financial Health Through Ratios - The Dwinnex

Can you still get a good price for Citius Pharmaceuticals Inc (CTXR) Shares at this point? - US Post News

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - The Malaysian Reserve

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Malaysian Reserve

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - PR Newswire

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance

You might want to take a look at Citius Pharmaceuticals Inc (CTXR) now - SETE News

Market Momentum Report: Citius Pharmaceuticals Inc (CTXR)’s Positive Close at 0.57 - The Dwinnex

Citius Pharmaceuticals Inc (CTXR) requires closer examination - US Post News

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Drop in Short Interest - MarketBeat

Arkadios Wealth Advisors Has $88,000 Holdings in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com India

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com Canada

In the Green: Citius Pharmaceuticals Inc (CTXR) Closes at 0.59, Up/Down -12.96 from Previous Day - The Dwinnex

It makes sense and dollars to buy Citius Pharmaceuticals Inc (CTXR) stock - SETE News

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com UK

Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Are Citius Pharmaceuticals Inc (CTXR) shares a good deal now? - US Post News

Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks

CTXRW (Citius Pharmaceuticals) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com

Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia

Vanguard Group Inc. Has $6.29 Million Stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World

Citius Oncology Inc. completes strategic acquisition - Investing.com

Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Canada

Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com UK

CTXRW (Citius Pharmaceuticals) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com

Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ

Citius Pharmaceuticals (NASDAQ:CTXR) Releases Quarterly Earnings Results - MarketBeat

Citius merges oncology subsidiary with TenX Keane - Yahoo Finance

Citius merges oncology subsidiary with TenX Keane - Pharmaceutical Technology

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - The Malaysian Reserve

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - StockTitan

Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024 - Marketscreener.com

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - StockTitan

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - BioSpace

Citius Pharmaceuticals Inc Inc. (CTXR) Price Performance: The Role of Supply and Demand - The InvestChronicle

Trading Day Review: Citius Pharmaceuticals Inc (CTXR) Loses Momentum, Closing at 0.78 - The Dwinnex

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Nasdaq

CTORCitius Oncology, Inc. Latest Stock News & Market Updates - StockTitan

Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year - AOL

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com

TenX Keane Acquisition Addresses Trading Halt, Continues - GlobeNewswire

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - StockTitan

FDA Greenlights Citius' Blood Cancer Therapy After Initial Rejection - Finimize

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection - Benzinga

New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online

US FDA approves Citius' therapy for rare blood cancer - Reuters.com

Citius wins FDA nod for lead drug Lymphir (NASDAQ:CTXR) - Seeking Alpha

FDA clears Citius’ IL-2 therapy Lymphyr for CTCL - BioWorld Online

CTXR과 유사한 종목